

# Resources for pharmacy program members

[www.vizientinc.com/PharmacySolutions](http://www.vizientinc.com/PharmacySolutions)

Visit our pharmacy webpage for web-based resources and the latest updates

*Log into My Dashboard on our website to access*

Contact us at [PharmacyQuestions@vizientinc.com](mailto:PharmacyQuestions@vizientinc.com)

SCAN ME



We are here to help



## Pharmacy Solutions

Sourcing, clinical and ambulatory support



## Analytics

Drug spend and clinical analytics platform



## Consulting Services

Operations, ambulatory, 340B, clinical



## Aggregation Groups

Pharmacy group purchasing & oncology network



## Navigating Vizient Pharmacy Analytics with Pharmacy Market Outlook projections and data

March 27, 2024

**vizient.**<sup>®</sup>



# Gain expert insights for pharmacy planning

A webinar series exploring new and hot topics from the recently published Pharmacy Market Outlook

## Navigating Vizient Pharmacy Analytics with PMO projections and data

**March 27, 1 p.m. CT**

Learn about the features and benefits of our new Pharmacy Portal and rebranded Pharmacy Analytics platform (formerly Vizient Savings Actualyzer – Pharmacy)

**TODAY!**

## Cell & gene therapy and specialty pharmaceuticals

**April 24, 1 p.m. CT**

There are 170+ gene and cellular immunotherapy products in the pipeline. Find out more about the novelty of gene therapy and the challenges it presents

SCAN TO  
REGISTER



# Housekeeping

- This call is being **recorded**
- Because of the large number of participants, all lines will be kept in **listen-only mode**
- **Questions** will be managed through the Q & A box



# Access and download

Visit the Pharmacy Market Outlook webpage where you can access and download the report as well as other resources

Click on the 'Access the report' button (in two places)

Pharmacy program participants  
Enjoy access to companion resources and additional information




[info.vizientinc.com/  
pharmacy-market-  
outlook-member-  
details](https://info.vizientinc.com/pharmacy-market-outlook-member-details)


Contact [PharmacyQuestions@vizientinc.com](mailto:PharmacyQuestions@vizientinc.com)

Also from this page...

Access the latest **Budget Impact Projections** report related to the healthcare supply chain



Read our new trends report and learn about strategies to grow revenue





# Vizient Pharmacy Analytics

## Formerly Savings Actualyzer – Pharmacy (VSAP)

### Now available!

- **Pharmacy Portal:** New user-friendly interface allowing a singular access point for pharmacy services and reporting
- **Pharmacy Analytics:** Available from the Pharmacy Portal with a new look and capabilities in addition to your favorite existing reports

- Real-time purchasing oversight
- Ability to customize views and schedule reports
- Insights and reporting into drug shortages, controlled medication, essential medications, biosimilars and more
- Data down to invoice level detail for a rolling 24 months

**Training:** Experience the new tools and ask questions of our analytics experts



Select a  
session that  
works for you

[vizientinc.com/learning-center/pharmacy-analytics-resources](https://vizientinc.com/learning-center/pharmacy-analytics-resources)

**Webinar:** Insights into emerging trends and success stories for Pharmacy Analytics

May 14, 1-2pm CT

SCAN TO  
REGISTER



Contact [PharmacyQuestions@vizientinc.com](mailto:PharmacyQuestions@vizientinc.com)



# Today's presenters



**Jeni Hayes, PharmD,  
MS, BCPS**

Sr Clinical Manager,  
Market Intelligence



**Richard Ponder, MBA,  
CMRP, CPhT, CPP,  
CEPP, PMC-VIII**

AVP, Spend Insights and  
Services

# Projected drug price inflation

## July 1, 2024 through June 30, 2025

This is our highest projected inflation rate since the July 2019 edition (January 2020 – December 2020 prediction window)

Several factors drive the trend of increasing inflation:

- Increase in specialty and ultra-specialty approvals
- Additional indications for previously approved medications, increasing utilization
- Products with higher-than-customary price increases
- Payer restrictions influencing site of care and class of trade implications for pharmacy services





# Vizient Pharmacy Analytics

With daily data feeds from 20+ distributors, Vizient pharmacy insights begin with visibility into \$130B+ in member spend (GPO eligible, 340B and WAC) across acute and non-acute care settings

Pharmacy program participants gain access to the Pharmacy Portal and Pharmacy Analytics as part of their Vizient pharmacy GPO participation


- Real-time purchasing oversight on a user-friendly interface
- Ability to customize views and schedule reports
- Insights and reporting into drug shortages, controlled medication, essential medications, hazardous medications, biosimilars, anesthesia gases and more
- Data down to invoice level detail for a rolling 24 months

- Category insights
- Market intelligence
- Contract optimization
- Program compliance
- Price assurance
- **Access to expert resource**

# Before

## Savings Actualyzer – Pharmacy (VSAP)

- Accessing took you to the Actualyzer platform dashboard
- From there, you would click on various reporting links to access information



# Now


## Access Pharmacy Analytics from the Pharmacy Portal

**Step 1:** Log in to **My Dashboard** on our website  
[vizientinc.com](https://vizientinc.com)

**Step 2:** Refer to **Quick Links** to find your available solutions

**Step 3:** Select the performance tile for **Pharmacy Portal**

If you need assistance, contact Member Support at [VizientSupport@vizientinc.com](mailto:VizientSupport@vizientinc.com)



◀ Go to **vizientinc.com**.


◀ Select **My Dashboard**.

◀ Refer to **Quick Links** to find your available solutions.

◀ Select the link for **Pharmacy Portal**.


# Pharmacy Portal & Pharmacy Analytics

- New **integrated experience** from the portal
- Portal **displays performance tiles that provide high-level metrics** and key performance indicators
- Use the system selection menu at the top left to select from your available systems and facilities




## Category insights

## Insights &amp; intelligence




- Market changes
- Provider vs. Market insights
- Trends, shifts, and shortages

## Opportunity Identification & Benchmarking



- Formulary alignment
- Benchmarking & peer compare
- Market share mix

## Margin Management & Monitoring




- Reimbursement
- Program compliance
- Contract optimization

# Price assurance

## Price Verification & Price Leveling

Vizient **contracted** products: **Six layers** of automated price verification service




**\$1.4B**  
Non-contract spend converted to contract spend

**\$74M**  
Net credits returned to providers

### Non-Vizient contracted products

- Parity in pricing across all account types
- **Price Leveling** – Within same class of trade, identifies variation in pricing



# Supply assurance

## Drug Shortage Insights report

Drug Shortage

Alternative Products

Shortage Status

Generic Name

All

All

All Products

Purchased Products

Not Purchased Products

Drug Shortage by Generic Name

Grid

Spend

# of NDCs on Shortage

Generic Name	Shortage Status	Shortage Start Date	Last Revised Date	# of NDCs on Shortage	Spend	Sold Qty	Ordered Qty
FLUTICASONE PROPIONATE	Resolved	3/30/2020	1/26/2024	8	\$ 55,313,345	329,204	439,958
IDARUBICIN HCL	Active	12/15/2023					
KETOROLAC TROMETHAMINE	Active	7/10/2015					
RANITIDINE HCL	No Longer Available	5/16/2018					
SODIUM ACETATE	Active	9/1/2021					

Drug Shortage by NDC

NDC Number	NDC Description
55150043810	KETAMINE HCL 10mg/mL VIAL 10 X 20 ML VIAL MUV, OUTER

- View identified drug shortages, including impacted NDCs
- Gain insight on causes and resupply estimates
- Identify when a shortage began and its status

Drug Shortage by NDC		NDC		NDC Details	
NDC Number	NDC Description	Shortage Status	Shortage Start Date	Last Revised Date	Spend
55150643810	KETAMINE HCL 10mg/mL VIAL 10 X 20 ML VIAL MUV, OUTER	Active	2/7/2018	3/4/2024	\$ 4,519,713
00409205105	KETAMINE HCL 100mg/mL VIAL 10 X 5 ML VIAL MUV, OUTER	Active	2/7/2018	3/4/2024	\$ 1,547,778
00143950010	KETAMINE HCL 50mg/mL VIAL 10 X 10 ML VIAL OUTER,MDV	Active	2/7/2018	3/4/2024	\$ 713,834
00143950910	KETAMINE HCL 100mg/mL VIAL 10 X 5 ML VIAL OUTER,MDV	Active	2/7/2018	3/4/2024	\$ 575,392
55150643910	KETAMINE HCL 50mg/mL VIAL 10 X 10 ML VIAL MUV, OUTER	Active	2/7/2018	3/4/2024	\$ 429,492
42823011310	KETALAR (ketamine HCl) 10mg/mL VIAL 10 X 20 ML VIAL STERIL VIAL, MUV	Active	2/7/2018	3/4/2024	\$ 235,889
55150644010	KETAMINE HCL 100mg/mL VIAL 10 X 10 ML VIAL MUV, OUTER	Active	2/7/2018	3/4/2024	\$ 6,816
42823011410	KETALAR (ketamine HCl) 50mg/mL VIAL 10 X 10 ML VIAL 10'S,MDV	Active	2/7/2018	3/4/2024	\$ 3,466
Sold Qty					
Ordered Qty					
Select a single NDC above to view Drug Shortage Reasons below:					
Shortage Reason(s)					
<ul style="list-style-type: none"> <li>• AuroMedics (Euglia) has ketamine on shortage due to increased demand.</li> <li>• Häma has ketamine injection on back order due to shortage of active ingredient.</li> <li>• Mylan Institutional divested ketamine to AuroMedics.</li> <li>• Par has Ketalar on back order due to shortage of active ingredient.</li> <li>• Pfizer has ketamine on shortage due to manufacturing delays.</li> </ul>					
Resupply Estimate Note(s)					
<ul style="list-style-type: none"> <li>• Euglia has ketamine 50 mg/mL, 10 mL vials and 100 mg/mL, 10 mL vials on long-term back order and the company cannot estimate a release date. The 10 mg/mL, 20 mL vials are on intermittent back order and the company is releasing product as it becomes available.</li> <li>• Häma has ketamine 100 mg/mL, 5 mL vials and 50 mg/mL, 10 mL vials on allocation.</li> <li>• Par has all Ketalar presentations on long-term back order and the company cannot estimate a release date.</li> <li>• Pfizer has ketamine 50 mg/mL, 10 mL vials on back order and the company estimates a release date of January 2025. The 100 mg/mL, 5 mL vials are on back order and the company estimates a release date of April 2024.</li> </ul>					



# Supply assurance

## Drug Shortage Insights

View alternative  
equivalent products  
with recent supply in  
distribution channel

Drug Shortage

Alternative Products

Generic Drug Name

Manufacturer Name

NDC Number - Description

Drug Shortage

KETAMINE HCL VIAL

All

All

☐ Y  
☐ N

Products

Product Category <sup>1</sup>

NDC Number	NDC Description	Generic Drug Name	Manufacturer Name	Drug Shortage
00143950801	KETAMINE HCL 50mg/mL VIAL 1 X 10 ML VIAL INNER,MDV	KETAMINE HCL VIAL	WEST-WARD/HIKMA	N
00143950810	KETAMINE HCL 50mg/mL VIAL 10 X 10 ML VIAL OUTER,MDV	KETAMINE HCL VIAL	WEST-WARD/HIKMA	Y
00143950901	KETAMINE HCL 100mg/mL VIAL 1 X 5 ML VIAL INNER,MDV	KETAMINE HCL VIAL	WEST-WARD/HIKMA	N
00143950910	KETAMINE HCL 100mg/mL VIAL 10 X 5 ML VIAL OUTER,MDV	KETAMINE HCL VIAL	WEST-WARD/HIKMA	Y
00409004005	KETAMINE HCL 100mg/mL VIAL 1 X 5 ML VIAL MUV, INNER	KETAMINE HCL VIAL	HOSPIRA-NOVAPLU	N
00409004010	KETAMINE HCL 100mg/mL VIAL 10 X 5 ML VIAL MUV, OUTER	KETAMINE HCL VIAL	HOSPIRA-NOVAPLU	N
00409205105	KETAMINE HCL 100mg/mL VIAL 10 X 5 ML VIAL MUV, OUTER	KETAMINE HCL VIAL	HOSPIRA/PFIZER	Y
00409205115	KETAMINE HCL 100mg/mL VIAL 1 X 5 ML VIAL MUV, INNER	KETAMINE HCL VIAL	HOSPIRA/PFIZER	N
00409205310	KETAMINE HCL 50mg/mL VIAL 10 X 10 ML VIAL MUV, OUTER	KETAMINE HCL VIAL	HOSPIRA/PFIZER	Y
00409205320	KETAMINE HCL 50mg/mL VIAL 1 X 10 ML VIAL MUV, INNER	KETAMINE HCL VIAL	HOSPIRA/PFIZER	N

Supply Strength: Low

High

Moderately High

Moderate

Low

None

Alternative Equivalent Products  
with Recent Supply in Distribution Channel <sup>1</sup>

On Viz Contract

Pkg Size Match

N+ Flag

NES Flag

NES-R Flag

Alt Generic Name

Alt Manufacturer Name

All

All

☐ Y  
☐ N

☐ Y  
☐ N

☐ Y  
☐ N  
☐ M

☐ Y  
☐ N

☐ Y  
☐ N

Alt NDC Number	Alt NDC Description	Alt Generic Drug Name	Alt Manufacturer Name	On Viz Contract	Pkg Size Match	N+ Flag	NES Flag	NES-R Flag
00409004010	KETAMINE HCL 100mg/mL VIAL 10 X 5 ML VIAL MUV, OUTER	KETAMINE HCL VIAL	HOSPIRA-NOVAPLU	Y	Y	Y	Y	Y
00409205115	KETAMINE HCL 100mg/mL VIAL 1 X 5 ML VIAL MUV, INNER	KETAMINE HCL VIAL	HOSPIRA/PFIZER	N	N	N	N	N

# Supply assurance

In specific reports, such as Contract Optimization, you can identify NDCs associated with our Novaplius, Novaplius Enhanced Supply (NES), and NES-Reserve programs.



- Highest rated private label
- Market-leading financial value
- Two labels to serve all members
- Higher fill rates for Vizient members
- 80% compliance earns rebates

972+ NDCs



## Enhanced Supply

All the value of Novaplius, AND

- Up to 6-month additional inventory
- Prioritizes essential medications
- Pooled inventory based on Vizient members' total historical purchases
- Protects entire pharmacy
- Purchasing NES NDCs drives additional inventory
- 80% compliance earns rebates

507+ NDCs



## Enhanced Supply Reserve

All the value of NES, AND

- Dedicated inventory based on member's total historical purchases
- Increased savings over NES via higher rebates
- Expanded Failure-to-Supply accounts for indirect shortage costs, such as labor
- 90% compliance earns rebates
- Member enrollment process

270+ NDCs

# Supply Assurance

## Advanced Access Hub


From the portal, you can also access the Advanced Access Hub

- Transparency into additional inventory for essential medications
- Inventory-related metrics and insights



# Advanced Analytics

- Spend analysis including spend overview dashboard
- Drug analysis including drug conversion opportunities



# Drug Budget Forecast report

Available to all organizations  
that participate in the Vizient  
pharmacy program

Personalizes the  
projections from the  
**Pharmacy Market Outlook**  
with your own spend data

- High level projection analysis and overview
- Detailed report with data filters and dynamic fields
- Editable within portal and exportable

Drug Budget Forecast ⓘ

System

Timeframe

PSM Demo Parent - 3270653

Feb-2023 - Jan-2024

Overview

Details

Total Spend	Analyzed Spend	Analyzed Spend %	Projected Inflation Impact ⓘ	Projected Inflation % ⓘ	Projected Analyzed Spend	Total Projected Spend
\$ 534,892,999	\$ 467,381,271	87.4 %	\$ 17,820,516	3.8 %	\$ 485,201,787	\$ 552,629,453

View Top 10 ▾ by Therapeutic Class Enhanced ▾

Total Spend

Inflation Impact

Therapeutic Class Enhanced	Total Spend	My % of Total Spend	Projected Inflation Impact	Analyzed Spend	Projected Inflation %	Projected Analyzed Spend	Total Projected Spend
Antineoplastics	\$ 187,311,476	35.0 %	\$ 6,667,174	\$ 181,540,221	3.7 %	\$ 188,207,395	\$ 193,978,650
Respiratory Therapy Agents	\$ 58,581,089	11.0 %	\$ 2,734,542	\$ 52,956,782	5.2 %	\$ 55,691,324	\$ 61,231,569
Biologicals	\$ 54,279,197	10.1 %	\$ 1,830,480	\$ 42,900,089	4.3 %	\$ 44,730,569	\$ 56,109,677
Hematological Agents	\$ 48,391,296	9.0 %	\$ 888,486	\$ 40,974,778	2.2 %	\$ 41,863,263	\$ 49,279,781
Endocrine	\$ 36,743,366	6.9 %	\$ 1,402,440	\$ 32,552,737	4.3 %	\$ 33,955,178	\$ 38,145,806
Anti-Infective Agents	\$ 22,706,531	4.2 %	\$ 738,840	\$ 17,797,113	4.2 %	\$ 18,535,953	\$ 23,445,371
Analgesic, Anti-inflammatory or Antipyretic	\$ 21,600,462	4.0 %	\$ 393,635	\$ 18,313,172	2.1 %	\$ 18,706,807	\$ 21,994,097
Multiple Sclerosis Agents	\$ 17,967,725	3.4 %	\$ 966,334	\$ 17,967,472	5.4 %	\$ 18,933,806	\$ 18,934,058

# Current insights


# Price Changes through February 2024

Contract Drug Price Increase/Decrease		No Contract Drug Price Increase/Decrease		Overall Drug Price Increase/Decrease	
Contract drugs are those drugs that are under contract with Vizient GPO, and thus under certain price control and communication contractual guidelines.		No Contract drugs are those drugs that are NOT under contract with Vizient GPO, and thus had no pricing control or communication contractual guidelines.		The overall impact of BOTH Contract and No Contract drug price increase/decrease.	
Net Impact of Drug Price Changes	% of Total Spend	Net Impact of Drug Price Changes	% of Total Spend	Net Impact of Drug Price Changes	% of Total Spend

## Historical Tracker

	2023	Jul-2023	Aug-2023	Sep-2023	Oct-2023	Nov-2023	Dec-2023	Jan-2024	Feb-2024
Annualized Spend	\$607,880,340	\$127,198,083,336	\$144,535,841,810	\$127,033,390,945	\$143,715,016,729	\$144,685,603,535	\$143,367,716,940	\$139,661,790,056	\$137,115,436,372
Annualized Contract Price Changes	(\$686,823)	+\$10,952,307	(\$1,651,723)	(\$4,317,103)	+\$73,767,032	+\$26,354,878	(\$3,374,326)	+\$316,817,979	(\$28,166,036)
Annualized No Contract Price Changes	\$64,034,814	+\$159,219,263	+\$1,068,955	+\$20,038,634	(\$266,768)	+\$11,982,619	+\$16,955,360	+\$1,158,967,594	+\$18,798,270
Annualized Total Price Changes	\$63,347,991	+\$170,171,569	(\$582,768)	+\$15,721,530	+\$73,500,264	+\$38,337,498	+\$13,581,033	+\$1,475,785,573	(\$9,367,766)
% Change	+0.05 %	+0.13 %	(0.00 %)	+0.01 %	+0.05 %	+0.03 %	+0.01 %	+1.06 %	(0.01 %)

## Historical Tracker - Net Price Change






# Price quantity mix insights

Jan. to June 2023

*versus*

July to Dec. 2023




# Price quantity mix insights

Sept. to Nov. 2023

*versus*

Dec. 2023 to Feb. 2024




# Price quantity mix insights

## Drill down to therapeutic class

Sept. to Nov. 2023

versus

Dec. 2023 to Feb. 2024



# Pharmacy Analytics

## Rx GPO participant vs. Subscription

Explore	Membership	Subscription
Benchmark Opportunities		•
Price Leveling		•
Price Change Impact Insights		•
Contract Optimization	•	•
Drug Shortage Report Insights	•	•

Monitor	Membership	Subscription
Spend Overview Trends	•	•
Market Share Optimization		•
Drug Budget Forecast	•	•
Price Quantity Mix		•
Essential Medication Insights	•	•
Controlled Substance Insights		•
Failure to Supply Insights	•	•
Price Verification Insights	•	•
CMS Outpatient Reimbursement		•

Resource	Membership	Subscription
Consultant		•

Toolbox	Membership	Subscription
Advance Analytics		•
Benchmark Price Performance		•
Benchmark Line-Item Detail		•
Peer Compare Insights		•
Pharmacy Spend Reports		•
Hazardous Drug Insights	•	•
Advanced Drug Analysis		•
Anesthesia Gases Report	•	•
Biosimilar Conversion Trends		•
High Dose IV Iron Trends		•

Price Verification services	Membership	Subscription
Non-contract to contract	•	•
Contract to contract		•
Tier		•
DSH		•

# Pharmacy Learning Center

## Register for instructor-led and access learning resources

- Pharmacy Analytics
- Pharmacy Value Tracker (PVT)
- Advanced Access Hub
- Site of Care Database

Contact [PharmacyQuestions@vizientinc.com](mailto:PharmacyQuestions@vizientinc.com)

The screenshot shows the Pharmacy Learning Center website. At the top, there's a header with the title 'Pharmacy Learning Center' and a 'Welcome!' message. Below this, a navigation bar includes links for 'Frequently Accessed', 'Upcoming Events', 'Webinar', 'Resources', and 'Meet the Experts'. A search bar is positioned below the navigation bar. The main content area is divided into two columns: 'Frequently Accessed' and 'Upcoming events'. The 'Frequently Accessed' column features a 'Pharmacy Portal' card with a 'New' badge and a description of the portal's purpose. The 'Upcoming events' column displays a table of events with columns for 'Title', 'Start Date', and 'End Date'. Below the events table, there's a section titled 'Empowering the Pharmacy Enterprise' with a description and a '2 Likes' indicator. At the bottom, there's a 'Vizient Pharmacy Resources' section.

Title	Start Date	End Date
Navigating the new Pharmacy Portal and Pharmacy Analytics platform with PMO projections and data	3/27/2024 1:00 PM	3/27/2024 2:00 PM
NEW! Pharmacy Analytics Training	3/28/2024 2:00 PM	3/28/2024 3:00 PM
NEW! Pharmacy Analytics Training	3/29/2024 10:00 AM	3/29/2024 11:00 AM
NEW! Pharmacy Analytics Training	4/1/2024 2:00 PM	4/1/2024 3:00 PM
NEW! Pharmacy Analytics Training	4/3/2024 2:00 PM	4/3/2024 3:00 PM
NEW! Pharmacy Analytics Training	4/5/2024 10:00 AM	4/5/2024 11:00 AM
Pharmacy Portal and Pharmacy Analytics Overview	4/10/2024 3:00 PM	4/10/2024 4:00 PM
Pharmacy Analytics Additional Insights (Part 1) Explore & Monitor	4/17/2024 3:00 PM	4/17/2024 4:00 PM
Pharmacy Portal and Pharmacy Analytics Overview	4/24/2024 10:00 AM	4/24/2024 11:00 AM
Pharmacy Analytics Additional Insights (Part 2) Toolbox	4/24/2024 3:00 PM	4/24/2024 4:00 PM

[vizientinc.com/learning-center/pharmacy-analytics-resources](https://vizientinc.com/learning-center/pharmacy-analytics-resources)



# Vizient Pharmacy Analytics

## Formerly Savings Actualyzer – Pharmacy (VSAP)

### Now available!

- **Pharmacy Portal:** New user-friendly interface allowing a singular access point for pharmacy services and reporting
- **Pharmacy Analytics:** Available from the Pharmacy Portal with a new look and capabilities in addition to your favorite existing reports

- Real-time purchasing oversight
- Ability to customize views and schedule reports
- Insights and reporting into drug shortages, controlled medication, essential medications, biosimilars and more
- Data down to invoice level detail for a rolling 24 months

**Training:** Experience the new tools and ask questions of our analytics experts



Select a  
session that  
works for you

[vizientinc.com/learning-center/pharmacy-analytics-resources](https://vizientinc.com/learning-center/pharmacy-analytics-resources)

**Webinar:** Insights into emerging trends and success stories for Pharmacy Analytics

May 14, 1-2pm CT

SCAN TO  
REGISTER



Contact [PharmacyQuestions@vizientinc.com](mailto:PharmacyQuestions@vizientinc.com)



## Next steps

- Explore Pharmacy Portal and Pharmacy Analytics
- If you need access, email [vizientsupport@vizientinc.com](mailto:vizientsupport@vizientinc.com)
- Register for training sessions
- If interested in learning more, email: [richard.ponder@vizientinc.com](mailto:richard.ponder@vizientinc.com)



# Questions?



# Pharmacy program resources



# Gain expert insights for pharmacy planning

A webinar series exploring new and hot topics from the recently published Pharmacy Market Outlook

## Navigating Vizient Pharmacy Analytics with PMO projections and data

**March 27, 1 p.m. CT**

Learn about the features and benefits of our new Pharmacy Portal and rebranded Pharmacy Analytics platform (formerly Vizient Savings Actualyzer – Pharmacy)

**TODAY!**

## Cell & gene therapy and specialty pharmaceuticals

**April 24, 1 p.m. CT**

There are 170+ gene and cellular immunotherapy products in the pipeline. Find out more about the novelty of gene therapy and the challenges it presents

SCAN TO  
REGISTER



# Access and download

**vizient**

What we do Our solutions Why we serve Case Studies Resources My Dashboard

Prepare for the future:  
The Pharmacy Market  
Outlook is now available

Stay informed. Navigate trends. Drive strategic decisions. Use this comprehensive report from our pharmacy experts for drug price forecasts and in-depth market analysis.

Scroll to learn more

Where to focus in 2024 Access now Pharmacy program participants

Where to focus in 2024

GLP-1 medication use has doubled in the past three years

8%

Projected overall drug price inflation rate for July 1, 2024 – June 30, 2025

Notes of provider calls for the treatment of obesity will increase by 175% in the year and 1,075% at 10 years. Further increasing the demand and resulting spend for this class of medications.

Source: IQVIA

Access now

Empower your decision-making with our new projections and insights. Download the latest drug budget forecasts and market analysis, essential for staying ahead in the evolving pharmaceutical landscape.

Get actionable insights from this report

Access the report

Pharmacy program participants

Enjoy access to companion resources and additional information

- Executive summary
- Letter to the reader regarding the pharmacy enterprise
- Timeline and approach
- A closer look by segment
- Key therapeutic class highlights and special populations
- Next steps
- Drug Budget Forecast reporting solution
- Pharmacy Market Outlook research webinar
- Pharmacy Market Outlook Research member webinar

Visit the Pharmacy Market Outlook webpage where you can access and download the report as well as other resources

Click on the 'Access the report' button (in two places)

Pharmacy program participants

Enjoy access to companion resources and additional information




[info.vizientinc.com/  
pharmacy-market-  
outlook-member-  
details](https://info.vizientinc.com/pharmacy-market-outlook-member-details)

Contact [PharmacyQuestions@vizientinc.com](mailto:PharmacyQuestions@vizientinc.com)

## Also from this page...

Access the latest **Budget Impact Projections** report related to the healthcare supply chain



Read our new trends report and learn about strategies to grow revenue

# Helpful communications

<b>Pharmacy Hot Info</b>	Weekly newsletter with contract price changes, advocacy updates, upcoming webinars
<b>Pharmacy Monitor</b>	Monthly clinical insights
<b>Pharmacy Sourcing Forum call</b>	<ul style="list-style-type: none"><li>• Third Wednesday of every month</li><li>• Contract updates and other important news related to vaccines, drug shortages, product access</li></ul>
<b>Pharmacy Institute</b>	Pharmacy Solutions training and overview for new members or individuals new to their role
<b>VerifiedRx</b>	<ul style="list-style-type: none"><li>• Pharmacy podcast with the latest news to support the strategic role of pharmacy</li><li>• New episodes second Tuesday of each month</li></ul>


Contact us at [PharmacyQuestions@vizientinc.com](mailto:PharmacyQuestions@vizientinc.com)

# We are here to help



## Pharmacy Solutions

Sourcing, clinical and ambulatory support



## Analytics

Drug spend and clinical analytics platform



## Consulting Services

Operations, ambulatory, 340B, clinical



## Aggregation Groups

Pharmacy purchasing groups & oncology network

Contact us at [PharmacyQuestions@vizientinc.com](mailto:PharmacyQuestions@vizientinc.com)

# Let's work together

---

# vizient<sup>®</sup>

Contact [PharmacyQuestions@vizientinc.com](mailto:PharmacyQuestions@vizientinc.com) for more information

This information is proprietary and highly confidential. Any unauthorized dissemination, distribution or copying is strictly prohibited. Any violation of this prohibition may be subject to penalties and recourse under the law. Copyright 2024 Vizient, Inc. All rights reserved.